Clinical value of detection on serum monocyte chemotactant protein-1 and vascular endothelial cadherin levels in patients with acute cerebral infarction

Xia Zhou1, Cheng Zhang2*

1Department of Neurology, the Third People’s Hospital, Zigong 643020, Sichuan Province, China
2Department of Neurosurgery, the Third People’s Hospital, Zigong 643020, Sichuan Province, China

ARTICLE INFO

Article history:
Received 28 Jul 2016
Accepted 22 Aug 2016
Available online 21 Sep 2016

Keywords:
Acute cerebral infarction
Monocyte chemotactant protein-1
Vascular endothelial cadherin
Interleukins
Matrix metalloproteinases

ABSTRACT

Objective: To study the correlation of serum monocyte chemotactant protein-1 (MCP-1) and vascular endothelia cadherin (VE-cadherin) levels in patients with acute cerebral infarction, and nerve injury molecules, interleukins and matrix metalloproteinases.

Methods: A total of 86 patients with acute cerebral infarction treated in our hospital from April 2012 to October 2015 were selected as the observation group and 50 healthy subjects in the same period treated in our hospital were selected as the control group. The serums were collected and the contents of MCP-1, VE-cadherin, heart-type fatty acid binding protein (H-FABP), S100 calcium binding protein B (S100B), neuron-specific enolase (NSE), interleukin-1β (IL-1β), IL-6, IL-17, IL-18, matrix metalloproteinase-2 (MMP2), MMP3 and MMP9 were measured.

Results: The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in observation group were significantly higher than those of control group. Carotid artery plaque formation and unstable plaque properties will increase the serum contents of MCP-1, VE-cadherin, heart-type fatty acid binding protein (H-FABP), S100 calcium binding protein B (S100B), neuron-specific enolase (NSE), interleukin-1β (IL-1β), IL-6, IL-17, IL-18, matrix metalloproteinase-2 (MMP2), MMP3 and MMP9 were measured.

Conclusions: The serum levels of MCP-1 and VE-cadherin were significantly increased in patients with acute cerebral infarction. MCP-1 and VE-cadherin can increase the secretion of interleukins and matrix metalloproteinases, which can result in the carotid artery plaque formation, unstable plaque properties and the injury of nerve function.

1. Introduction

Acute cerebral infarction is one of the cardiovascular and cerebrovascular diseases seriously threatening to human health with high disabling rate and increased morbidity year by year and the morbidity crowd has a trend of rejuvenation. Cerebral infarction can cause hypoxic-ischemia necrosis of brain tissue and leave the varying degrees of dysfunction, which will have a serious impact on patients’ daily life and work[1-3]. Thus, how to screen high-risk groups, early diagnose disease and determine the severity of the disease has been a hot spot in clinical research. Carotid atherosclerosis is an independent risk factor to cause acute cerebral infarction and inflammatory response is an important pathological change through carotid atherosclerosis in all aspects. After the vascular endothelium is injured, the infiltrating inflammatory mediators above. Local ischemia and hypoxia caused by cerebral infarction and the ischemia reperfusion by
the treatment of intervention or thrombolysis will cause local excessive inflammatory response of the brain tissue and mediate the injury of neural function by ILs and MMPs and other mediators[7–10].

Monocyte chemotactic protein-1 (MCP-1) and vascular endothelial cadherin (VE-cadherin) are the important molecules to modulate inflammatory cell chemotaxis and adhesion to the lesion. In the course of the pathology of injury of neural function after carotid atherosclerosis and cerebral infarction, MCP-1 and VE-cadherin may be the upstream factor to regulate inflammation response and promote the infiltration of inflammatory cells and the release of inflammatory mediators[11–16]. However, the present specific change of MCP-1 and VE-cadherin in patients with acute cerebral infarction is not clear. Besides, the correlation between MCP-1, VE-cadherin and the release of inflammatory mediators and the injury of neural function has not been reported. In the present study, the serum levels of MCP-1 and VE-cadherin in patients with acute cerebral infarction and the correlation with ILs, MMPs and other inflammatory mediators were analyzed.

2. Materials and methods

2.1. Research objects

A total of 86 patients with acute cerebral infarction treated in our hospital from April 2012 to October 2015 and 50 healthy subjects treated in our hospital in the same period were selected to perform prospective study, which was approved by Hospital Ethics Committee. Patients with acute cerebral infarction were served as observation group, with the inclusion criteria as follows: 1. In line with the diagnostic criteria of acute cerebral infarction in the Fourth National Cerebrovascular Disease Conference; 2. The onset time not exceeded 72 h and duration of symptoms for more than 24 h; 3. The brain CT and magnetic resonance imaging were used to confirm the presence of the corresponding to the function of cerebral infarction. Patients with intracerebral hemorrhage, severe heart and lung diseases or hepatic and kidney function obstacle and patients with history of infection in nearly one month were excluded. The 50 healthy subjects were served as control group, excluding patients with a history of acute or chronic inflammatory disease combined with peripheral vascular diseases or thrombotic disease.

2.2. Evaluation methods of carotid plaques properties

After admission for 1 week, carotid ultrasonography was undergone with transducer frequency of 7.5 MHz. The detection range was from carotid artery distal 2.0 cm to internal carotid artery and external carotid artery proximal 1.0 cm, measuring the intima-media thickness of multiple parts. Any side of carotid artery intima-media thickness with more than 1.5 mm was judged as plaque formation, with 1.0–1.5 mm as the thickening of intima and with less than 1.0 mm as a normal intima. The parts in the carotid plaque area were scanned again. If the echo intensity was higher than that of vessel wall, it was judged as high echo plaques; if uneven, it was judged as mixed echo plaques; if lower than that of vessel wall and the plaque highlighted in uterine cavity, it was judged as low echo plaques.

2.3. Evaluation methods of cerebral infarction volume

After admission, emergency CT examination was performed. The length, width and height of the lesion were measured after obtaining the images of cerebral infarction lesion and then the volume of infarction lesion was calculated. The calculating method was as follows:

\[
\text{Volume of infarction lesion (V, cm}^3\text{)} = \text{length (cm)} \times \text{width (cm)} \times \text{height (cm)} \times \pi/6.
\]

\(V < 5 \text{ cm}^3\) was considered as small area infarction, \(V = 5–10 \text{ cm}^3\) as middle area infarction, \(V > 10 \text{ cm}^3\) as large area infarction.

2.4. Serum specimen collections and detection methods

Patients in observation group were immediately collected 10 mL peripheral venous blood when admission to the hospital. The healthy subjects in control group were collected 10 mL peripheral venous blood when taking physical examination. After standing at room temperature for 10–15 min, they were centrifuged for 10 min at 12 000 r/min centrifugal force. Then, the upper serum was collected and the contents of MCP-1, VE-cadherin, heart-type fatty acid binding protein (H-FABP), S100 calcium binding protein B (S100B), neuron-specific enolase (NSE), IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 were measured by ELISA kits.

2.5. Statistical methods

The data were input and analyzed by SPSS version 19.0 software and the measurement data were performed by mean ± SD. The analyses between two groups were carried out by t-test and among three groups by ANOVA. The enumeration data were performed by frequency form and analyzed by Chi-square test. The correlations between two variables were verified by Pearson’s correlation analysis. Differences were statistically significant when \(P < 0.05\).

3. Results

3.1. General clinical data of two groups

In observation group, 86 patients included 51 males and 35 females, with (56.30 ± 7.80) years of age, body mass index (BMI) (23.14 ± 2.97) kg/m², 53 cases with high blood pressure, 24 cases with diabetes, 45 cases with smoking history. In control group, 50 patients included 29 males and 21 females, with (55.80 ± 8.60) years of age, BMI (22.48 ± 2.48) kg/m², 7 cases with high blood pressure, 3 cases with diabetes, 14 cases with smoking history. According to statistic analysis, there were no differences in sex, age and BMI in two groups, and cases with high blood pressure, diabetes and smoking history in observation group were significantly higher than those of in control group (Table 1).

3.2. Comparison of serum biochemical indexes in two groups

The analyses between two groups on serum biochemical indexes of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-
Table 1
The clinical data of two groups.

<table>
<thead>
<tr>
<th>Items</th>
<th>Observation group (n = 86)</th>
<th>Control group (n = 50)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>51/35</td>
<td>29/21</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>Age (years)</td>
<td>56.30 ± 7.80</td>
<td>55.80 ± 8.60</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.14 ± 2.97</td>
<td>22.48 ± 2.48</td>
<td>&gt; 0.05</td>
</tr>
<tr>
<td>High blood pressure</td>
<td>53 (61.63%)</td>
<td>7 (14.00%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Diabetes</td>
<td>24 (27.91%)</td>
<td>3 (6.00%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Smoking</td>
<td>45 (52.33%)</td>
<td>14 (28.00%)</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.

Table 2
Comparison of serum biochemical indexes in two groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Observation group (n = 86)</th>
<th>Control group (n = 50)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>362.32 ± 42.69</td>
<td>201.46 ± 28.79</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>VE-cadherin (μg/mL)</td>
<td>6.94 ± 0.89</td>
<td>3.56 ± 0.41</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>H-FABP (ng/mL)</td>
<td>0.89 ± 0.11</td>
<td>0.26 ± 0.04</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>S100B (ng/mL)</td>
<td>1.52 ± 0.19</td>
<td>0.42 ± 0.06</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>NSE (ng/mL)</td>
<td>9.62 ± 1.03</td>
<td>3.36 ± 0.45</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-1β (ng/mL)</td>
<td>8.59 ± 1.03</td>
<td>2.57 ± 3.41</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>19.48 ± 2.67</td>
<td>6.24 ± 0.93</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-17 (ng/mL)</td>
<td>16.84 ± 2.26</td>
<td>7.46 ± 0.93</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-18 (pg/mL)</td>
<td>32.58 ± 4.58</td>
<td>14.25 ± 2.16</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP2 (ng/mL)</td>
<td>83.42 ± 9.51</td>
<td>36.68 ± 5.16</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP3 (ng/mL)</td>
<td>70.14 ± 8.68</td>
<td>31.24 ± 4.69</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP9 (ng/mL)</td>
<td>286.56 ± 36.38</td>
<td>116.47 ± 14.57</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.

In observation group, the analyses of serum biochemical indexes of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with normal carotid intima, carotid intimal thickening and carotid intimal plaque formation were shown in Table 3. The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with carotid intimal thickening and carotid intimal plaque formation were significantly higher than those of patients with normal carotid intima. The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with carotid intimal thickening were significantly higher than those of patients with carotid intimal plaque formation. The differences of the pairwise comparison on serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with normal carotid intima, carotid intimal thickening and carotid intimal plaque formation were statistical significant (P < 0.05).

In observation group, the analyses of serum biochemical indexes of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in carotid plaques patients with high echo plaques, mixed echo plaques and low echo plaques are shown in Table 4. The contents of serum MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with mixed echo plaques and low echo plaques were significantly higher than those of patients with high echo plaques. The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with mixed echo plaques and low echo plaques were significantly higher than those of patients with high echo plaques. The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with low echo plaques were significantly higher than those of patients with mixed echo plaques. The differences of the comparison on serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1β, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with high echo plaques, mixed echo plaques and low echo plaques were statistical significant (P < 0.05).

Table 3
Serum biochemical indexes in observation group with normal carotid intima, carotid intimal thickening and carotid intimal plaque formation.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients with normal carotid intima (n = 17)</th>
<th>Patients with carotid intimal thickening (n = 29)</th>
<th>Patients with carotid intimal plaque formation (n = 40)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>282.93 ± 33.51</td>
<td>351.42 ± 37.32</td>
<td>436.48 ± 51.33</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>VE-cadherin (μg/mL)</td>
<td>4.34 ± 0.61</td>
<td>6.42 ± 0.77</td>
<td>8.31 ± 0.98</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>H-FABP (ng/mL)</td>
<td>0.44 ± 0.07</td>
<td>0.72 ± 0.09</td>
<td>1.15 ± 0.16</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>S100B (ng/mL)</td>
<td>0.84 ± 0.11</td>
<td>1.37 ± 0.17</td>
<td>1.94 ± 0.25</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>NSE (ng/mL)</td>
<td>6.33 ± 0.78</td>
<td>9.31 ± 0.93</td>
<td>12.47 ± 1.74</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-1β (ng/mL)</td>
<td>5.84 ± 0.71</td>
<td>7.93 ± 0.93</td>
<td>11.24 ± 1.53</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>10.33 ± 1.68</td>
<td>17.58 ± 2.24</td>
<td>25.67 ± 3.52</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-17 (ng/mL)</td>
<td>9.59 ± 1.14</td>
<td>14.68 ± 1.94</td>
<td>21.94 ± 2.94</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>IL-18 (pg/mL)</td>
<td>22.78 ± 3.47</td>
<td>30.93 ± 4.28</td>
<td>39.14 ± 5.41</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP2 (ng/mL)</td>
<td>57.94 ± 7.14</td>
<td>79.32 ± 8.69</td>
<td>103.48 ± 14.48</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP3 (ng/mL)</td>
<td>52.47 ± 6.23</td>
<td>68.65 ± 7.59</td>
<td>93.41 ± 10.35</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>MMP9 (ng/mL)</td>
<td>193.52 ± 22.57</td>
<td>272.47 ± 31.38</td>
<td>342.57 ± 41.38</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.
Inflammatory response is a pathological change of the various links in the process of atherosclerosis. Many kinds of inflammatory mediators involve in the formation of plaque, the change of property, the rupture of fibrous cap and the process of platelet activation and thrombosis. Carotid atherosclerosis is an independent risk factor to cause cerebral infarction, and plaque shedding into the brain will result in arterial embolism, blood flow interruption and ischemic injury of neurological function. While ischemia reperfusion caused by thrombolysis or interventional therapy will further activate the local excessive inflammatory response of the brain tissue, and then continue to cause injury of neural function through the inflammatory mediators\[15,16\]. In this study, the analyses of MCP-1 and VE-cadherin were important molecules to regulate the inflammatory cells in local lesions in cerebral infarction. MCP-1 is a member of the CC family of chemokines, which can promote the migration from mononuclear macrophages to the arterial intima and form foam cells, thereby accelerating the formation of atheromatous plaques\[17,18\]. VE-cadherin is a member of the family of E-cadherin, which connected with intracellular protein $\beta$-catenin through the end of carbon and transferred biological signals promoting the secretion of a variety of inflammatory factors\[19\]. The above research analyses have confirmed that the serum contents of MCP-1 and VE-cadherin in patients with cerebral infarction were significantly increased, which indicated that the increase of contents of MCP-1 and VE-cadherin is related to cerebral infarction.

Cerebral infarction will lead to the multiple molecules like H-FABP, S100B, NSE and other molecules in neurocyte releasing into the cerebrospinal fluid, thereby only the blood brain barrier getting into blood circulation. The contents of serum marker molecules H-FABP, S100B and NSE were detected to reflect the degree of nerve injury of cerebral infarction. H-FABP is a member of family of FABP participating in the transport and metabolism of fatty acids in the body and positioning in endochylema of nerve cells. S100B is a kind of acidic calcium binding protein highly expressed in neuron which can promote axonal growth and neuronal differentiation\[20,21\]. NSE is a kind of enolization dimer enzyme isozyme in neuron participating in the regulation of cellular energy metabolism\[22,23\]. Hypoxic-ischemia injury caused by cerebral infarction can lead to H-FABP, S100B and NSE getting into the blood circulation. The analyses of molecular contents in serum above confirmed that the serum contents of H-FABP, S100B and NSE in patients with cerebral infarction were significantly higher than those in healthy subjects with physical examination and positively related with the serum contents of MCP-1 and VE-cadherin. This suggested that the increase of contents of MCP-1 and VE-cadherin is related to the injury of neural function in patients with cerebral infarction. MCP-1 and VE-cadherin may cause nerve cell damage and the injury of neural function through mediating inflammatory response of infarction lesions.

Carotid atherosclerosis is an independent risk factor to cause cerebral infarction. Further analyses of the relationship of contents between carotid atherosclerosis and MCP-1 and VE-cadherin can get to know that the increase of contents of MCP-1 and VE-cadherin will form carotid artery plaque and change the property of plaque, which indicated that the increase of contents of MCP-1 and VE-cadherin not only participates in nerve cell damage, but also involves the formation of carotid artery plaque and the change of property. ILs and MMPs are the important mediators to mediate carotid atherosclerosis. IL-1$\beta$, IL-6, IL-17 and IL-18 are interleukin molecules with proinflammatory effects, which can not only lead to the trend from neutrophile granulocyte to carotid intimal and promote the formation of atheromatous plaque, but also infiltrate in atherosclerotic lesions and cause nerve cell damage\[24-27\]. MMP2, MMP3 and MMP9 play a role in degrading extracellular matrix. MMP in atheromatous plaque can degrade fibrous cap and cause the rupture of plaque and the change of property. MMP in the parts of brain ischemia and the ischemia reperfusion can damage the blood brain barrier and cause brain edema\[28,29\]. The analyses of the serum contents of ILs and MMPs in patients with cerebral infarction confirmed that the serum contents of IL-1$\beta$, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in observation group were significantly higher than those of control group and positively related with MCP-1 and VE-cadherin, which indicated that MCP-1 and VE-cadherin can promote the secretion of a variety of ILs and MMPs.

In conclusion, the serum levels of MCP-1 and VE-cadherin was significantly increased in patients with acute cerebral infarction. VE-cadherin and MCP-1 can increase the secretion of ILs and MMPs, which can result in the carotid artery plaque formation, unstable properties and the injury of nerve function.

**Conflict of interest statement**

The authors report no conflict of interest.
Acknowledgments

This work was financially supported by Scientific Research Project of Sichuan Provincial Ministry of Health (Project No. 120349).

References


